



Polymeric Nanoparticles for Immunotherapy of Cancer

Guest Editors:

Dr. Cristina Fornaguera

Grup d'Enginyeria de Materials
(GEMAT), Bioengineering
Department, Institut Químic de
Sarrià (IQS), School of
Engineering, Universitat Ramon
Llull (URL), Via Augusta 390,
08017 Barcelona, Spain

Dr. Marta Guerra-Rebollo

Grup d'Enginyeria de Materials
(GEMAT), Bioengineering
Department, Institut Químic de
Sarrià (IQS), School of
Engineering, Universitat Ramon
Llull (URL), Via Augusta 390,
08017 Barcelona, Spain

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

Cancer immunotherapeutics represents the cutting-edge alternative for an efficient treatment of many tumors. In recent years, advancements in the field have been huge, and cancer immunotherapy has currently become the standard of care for some tumors. However, for most internal tumors, although in vitro approximations of immunotherapy have demonstrated hints of success, their translation to in vivo is poor. This could be mainly attributed to the lack of efficient delivery systems that are required to ensure the required biodistribution. In this context, nanomedicine could represent a step forward for the application of immunotherapies in clinical practices. Polymeric nanoparticles have attracted increasing interest since their discovery thanks to the many advantages they represent for several biomedical applications.

This Special Issue suggested topics are cancer therapeutic vaccines, adoptive cell transfer therapies, and checkpoint inhibitor therapies, provided that all of them make use of nanomedicine, specifically of polymeric nanoparticles, to deliver the active principle.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma